PROTECT YOUR PATH TO APPROVAL WITH MEDIDATA RAVE TRIAL ASSURANCE

Machine learning improves data quality and scales to meet increasing demand

When analyzing data quality issues in

- **24** RECENT STUDIES

across

- **18** THERAPEUTIC AREAS

Rave Trial Assurance found

- **1479** AVOIDABLE DATA QUALITY ISSUES

spanning

- **30M+** DATA POINTS

and

- **22K** PATIENTS

learning

- **90K+** RULES

### Data Quality Issues Across 24 Studies

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
<th>Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inconsistencies in how sites evaluate or measure endpoints</td>
<td>670</td>
<td>24/24</td>
</tr>
<tr>
<td>Differences in the actions sites take with regard to an adverse event</td>
<td>417</td>
<td>24/24</td>
</tr>
<tr>
<td>Inconsistencies in how sites follow the protocol</td>
<td>225</td>
<td>22/24</td>
</tr>
<tr>
<td>Values that are impossible or highly unlikely due to data entry errors</td>
<td>158</td>
<td>9/24</td>
</tr>
<tr>
<td>Sites that make up data out of neglect or forgetfulness</td>
<td>9</td>
<td>3/24</td>
</tr>
</tbody>
</table>

### Anomaly Categories Detected

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
<th>Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inconsistencies in how sites evaluate or measure endpoints</td>
<td>670</td>
<td>24/24</td>
</tr>
<tr>
<td>Differences in the actions sites take with regard to an adverse event</td>
<td>417</td>
<td>24/24</td>
</tr>
<tr>
<td>Inconsistencies in how sites follow the protocol</td>
<td>225</td>
<td>22/24</td>
</tr>
<tr>
<td>Values that are impossible or highly unlikely due to data entry errors</td>
<td>158</td>
<td>9/24</td>
</tr>
<tr>
<td>Sites that make up data out of neglect or forgetfulness</td>
<td>9</td>
<td>3/24</td>
</tr>
</tbody>
</table>

### A Top 25 Global Pharma

Data Quality Issues most likely to delay regulatory approval in

- **26%**

  - **10** Studies in **6** Therapeutic Areas

### A Top Global Pharma with HQ in APAC

Data Quality Issues most likely to delay regulatory approval in

- **29%**

  - **1** Study in **1** Therapeutic Area

### A Top 10 Global Med-Device

Data Quality Issues most likely to delay regulatory approval in

- **37%**

  - **2** Studies in **2** Therapeutic Areas

The difference between an FDA approval and an FDA letter:

**Medidata Rave Trial Assurance**

- **Sponsor 1**
  - Medidata Rave Trial Assurance Extra Analyses
  - FDA Approval
  - Q1’ 2018 Launch

- **Sponsor 2**
  - FDA Letter Extra Analyses
  - Delay